Halozyme Therapeutics, Inc. (HALO)

Market Cap	6.97B
Revenue (ttm)	947.36M
Net Income (ttm)	392.47M
Shares Out	127.23M
EPS (ttm)	3.02
PE Ratio	18.13
Forward PE	11.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	904,572
Open	55.66
Previous Close	55.37
Day's Range	54.77 - 55.72
52-Week Range	33.15 - 65.53
Beta	1.23
Analysts	Buy
Price Target	60.89 (+11.11%)
Earnings Date	Feb 18, 2025

About HALO

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 373
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2023, Halozyme Therapeutics's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.

Analyst Forecast

According to 9 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $60.89, which is an increase of 11.11% from the latest price.

Price Target

$60.89

(11.11% upside)

Analyst Consensus: Buy